

7point assay validation

New Treatments. New Assays. Quick To Market.



With over 1,000 assays developed by us for the research and clinical market, we are in a position to develop assays in a competitive and quick manner. All our assays are validated and offer good reproducibility.

- ✓ 1. Sensitivity
- ✓ 2. Specificity
- ✓ 3. Precision - Inter Assay
- ✓ 4. Precision - Intra Assay
- ✓ 5. Spike / Recovery
- ✓ 6. Hook Curve
- ✓ 7. Stability

REFERENCES

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy
K Hermansen, S Madsbad, H Perrild... - Diabetes ..., 2001 - Am Diabetes Assoc

Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin
V Matheu, E Perez... - Clinical and ..., 2005 - clinical molecular allergy ...
... Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin. Víctor Matheu,; Eva Perez 2 ;; Marta Hernández 3 ;; Elisa Díaz 2 ;; Ricardo Darias 3 ;; Abel González 4 ;; Jose C García 2 ;; Inmaculada Sánchez 2 ;; ...

A new insulin immunoassay; for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies
L Andersen, PN Jørgensen, LB Jensen, D Walsh - Clinical biochemistry, 2000 - Elsevier

Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
L Heinemann, C Weyer, M Rauhaus... - Diabetes ..., 1998 - Am Diabetes Assoc

Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus
DJ Pettitt, P Ospina, JW Kolaczynski... - Diabetes Care, 2003 - Am Diabetes Assoc

Development of a long-acting insulin analog using albumin fusion technology
A Duttaroy, P Kanakaraj, BL Osborn, H Schneider... - Diabetes, 2005 - Am Diabetes Assoc

A novel insulin analog with enhanced β -cell protective action
I Rakatzi, G Seipke, J Eckel - Biochemical and biophysical research ..., 2003 - Elsevier

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
T Heise, L Nosek, BB Rønn, L Endahl, L Heinemann... - Diabetes, 2004 - Am Diabetes Assoc

F Mecacci, L Carignani, R Cioni, E Bartoli... - European Journal of ..., 2003 - Elsevier
... N. Engl. J. Med., 333 (1995), pp. 1237-1241. [6] JH Anderson Jr., RL Brunelle, VA Koivisto,

Insulin Analogs

Glargine / Aspart / Lispro

Monitor
Dosage Efficacy

Monitor
Antibodies

diabetes

GLP1 Agonists

Exendin-4 / Liraglutide /
Semaglutide / Lixisenatide



leading reagent supplier to
academicians, pharmaceutical
companies, clinical trial
organizations and clinicians



Assay kits offered by KRISHGEN for measurement of
GLP-1 receptor agonist medicines



KRISHGEN is a research-driven company founded on Research, Development and Producing reagents that improve health and quality of life.

Our Experience Counts. We Know The Needs.

We have been distributing reagents for the world's leading companies since 2003 and are abreast of the current unmet needs of the market. We aim to develop esoteric assays which are required by clinicians to enable better patient monitoring, and help in reducing patient management costs.

BIOSCIENCE making strides in pharmaceutical research

What are Insulin Analog medicines ?

An insulin analog is an altered form of insulin, different from any occurring in nature, but still available to the human body for performing the same action as human insulin in terms of glycaemic control.

Through genetic engineering of the underlying DNA, the amino acid sequence of insulin can be changed to alter its ADME (absorption, distribution, metabolism, and excretion) characteristics.

Officially, the U.S. Food and Drug Administration (FDA) refers to these as "insulin receptor ligands", although they are more commonly referred to as insulin analogs.

Fast Acting Insulin Analogs

Lispro
Aspart

Long Acting Insulin Analogs

Glargine insulin

LISPRO ELISA

Assay Type: Sandwich
Format: 96 well type
Quantitative
Assay Range: 0.2-12.8 ng/ml

GLARGINE ELISA

Assay Type: Sandwich
Format: 96 well type
Quantitative
Assay Range: 0.2-12.8 ng/ml

ASPART ELISA

Assay Type: Sandwich
Format: 96 well type
Quantitative
Assay Range: 0.2-12.8 ng/ml

ANTI-LISPRO ELISA

Assay Type: Sandwich
Format: 96 well type
Quantitative
Assay Range: 25-500 ng/ml

ANTI-GLARGINE ELISA

Assay Type: Sandwich
Format: 96 well type
Quantitative
Assay Range: 25-500 ng/ml


ANTI-ASPART ELISA

Assay Type: Sandwich
Format: 96 well type
Quantitative
Assay Range: 25-500 ng/ml

What are GLP-1 receptor agonist medicines ?

GLP-1 receptor agonist medicines, also called incretin mimetics, are a type of incretin-based medicine for type 2 diabetes. This type of medicine is based on the action of hormones called incretins, which help control how the pancreas works. One type of incretin, called GLP-1, causes your pancreas to produce more insulin after you eat and helps keep blood glucose levels in the normal range.

These medicines (exanatide, lixisenatide, liraglutide and semaglutide) copy, or mimic, the action of GLP-1 made by your body. The effects of GLP-1 only last for a few minutes, but GLP-1 receptor agonists medicines can last for hours or days.





EXENATIDE ELISA

Assay Type: Sandwich
Format: 96 well type
Quantitative
Assay Range: 1-30 ng/ml

LIXISENATIDE ELISA

Assay Type: Sandwich
Format: 96 well type
Quantitative
Assay Range: 1-30 ng/ml



LIRAGLUTIDE ELISA

Assay Type: Competitive
Format: 96 well type
Quantitative
Assay Range: 12.35-1000 pg/ml

SEMAGLUTIDE ELISA

Assay Type: Competitive
Format: 96 well type
Quantitative
Assay Range: 0.25-8 ng/ml

